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The liver has a far more complicated metabolism than other 
transplanted organs and malfunction leads to more complex 
physiologic derangements. Patients with liver disease are fur-
ther handicapped by the lack of satisfactory means of artificial 
support comparable to renal dialysis. The transplanted liver 
must function efficientlv from the time of anastomosis, or the 
patient may be lost. Despite these and other difficulties, the 
therapeutic power and appeal of liver transplantation has had a 
pervasive impact on hepatology and liver surgery. Today, it is 
difficult to envision a hepatology center without the capability 
for transplantation. Almost all victims of nonneoplastic chronic 
liver disease can at least be considered for liver transplantation, 
and even some of those with malignant hepatic tumors may be 
benefited. Acute liver disease was rarely suggested as a reason 
to consider liver transplantation until the mid 1980s, but now 
the rescue by this means of patients with fulminant hepatitis is 
common. Human survival of more than 20 years after liver 
transplantation has been achieved. 
There are two general approaches to transplantation of the 
liver. With the first method, the host liver is removed and re-
placed with a homograf.t (orthotopic transplantation) (Fig. 1). 
The alternative technique is the insertion of an extra liver (auxil-
iary homotransplantation) at an ectopic site (Fig. 2). Both proce-
dures were developed in dogs and later studied in other species, 
including rats, pigs, monkeys, and humans. The most encourag-
ing results have been with orthotopic transplantation, for which 
reason this chapter is concerned primarily with this replacement 
operation. However, long survival has also been accomplished 
with auxiliary hepatic transplantation, and this option is briefly 
considered in a special section. 
IMMUNOLOGIC CONSIDERATIONS 
Is the liver a privileged graft? When liver replacement was 
first successfully performed in dogs, immunosuppression was 
discontinued after 4 months. A surprising number of animals 
continued to thrive either with no signs of rejection or with 
remittent rejection episodes.9 One such dog lived in the authors' 
laboratory for more than 11 years after transplantation. The 
phenomenon of "graft acceptance" has been noted in dogs with 
renal transplants, although less frequently. The apparently im-
munologic advantage of the liver has been more clearly noted in 
pigs, some of which can survive chronically with no immuno-
suppressive therapy, despite the fact that the pigs regularly re-
ject skin and kidney grafts. 
In later years, numerous studies in inbred rats with known 
Figur. 1. Orthotopic liver transplantation (liver repjacement). Bifiary tract recon-
struction is usually done with choIedochojejunostomy (to a Raux ~mbF Of (inset) 
with a cho4edochochoIetOfnY. which is stented With aT-tube. (From Starzl. 
T. E •• 0emetr1s. A. J .. and Van Thiel. D. H.: Medical progress: Uvertranspiantation. 
N. Engl. J. Mad .• 321:1014.1989.) 
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Figure 2. Auxiliary liver transplantation with a technique that provided an ade-
quate blood supply for the homograft. Note that the transplant is given a double 
blood supply and that the venous component is from the non hepatic splanchnic 
bed. Biliary drainage can be with a Aoux~-v cholecystolejunostomy. 
histocompatibility barriers have confirmed that the liver is more 
resistant to rejection than any other major organ. Permanent 
acceptance can be routinely induced in rats across major histo-
compatibility barriers with only 3 or 4 injections of immuno-
suppressive drugs during the early postoperative period.8 
Nearly a year later, the recipient animals retain an intact immu-
nologic apparatus including the ability to vigorously reject skin 
from the original donor species. This kind of graft acceptance of 
hearts, kidneys, and other organs is much more difficult to 
achieve. 
Another important advantage of the liver is resistance to anti-
body-mediated (humoral) rejection. Whereas kidneys and 
hearts usually are destroyed by hyperacute rejection in patients 
whose serum contains cytotoxic antibodies of the IgG class 
which are directed against HLA and other antigens in the donor, 
livers are spared this fate in most cases. The pathogenesis of 
hyperacute rejection includes obstruction of the microvascula-
ture of nonhepatic grafts with clotting products and formed 
blood elements. This process usually does not occur in liver 
grafts, and what can be expected clinically is an unusually vig-
orous cellular rejection that can be treated with aggressive con-
ventional immunosuppression. The practical implication is that 
a negative cytotoxic crossmatch that is a necessary condition for 
transplantation of other organs is not required for successful 
liver transplantation. Moreover, it has been established that the 
liver can provide a protective screen for otherwise vulnerable 
kidneys in highly sensitized recipients who need both a liver 
and a kidney. In such patients who receive a liver first, the titer 
of antidonor antibodies is drastically reduced during the first 
few hours after hepatic revascu1arization, making it possible 
then to insert a kidney from the liver donor without periJ.3 
The reasons the liver has these advantages are not under-
stood. Whatever the explanation, overstatement of the case for 
the liver's privileged status could lead to erroneous conclusions 
about the practical requirements for immunosuppressive ther-
apy following hepatic transplantation in man. In humans, con-
trol of hepatic rejection may be difficult or impossible despite 
very heavy immunosuppressive therapy. 10 When routine biop-
sies are obtained in patients after orthotopic liver transplanta-
tion, histopathologic evidence of rejection can be found in more 
than two thirds of patients. Effective management of this com-
plication is the key to successful transplantation. 
REJECTION REVERSAL 
Rather than being unique, it is probable that liver homografts 
differ from other organs only by the degree of the host immuno-
logic response they evoke. This has been demonstrated with 
genetically standardized inbred rat strains, and exceptionally 
clearly in mouse models in which knowledge of the major histo-
compatibility complex is even more complete. In this context, 
two key observations initially made with kidneys have been 
extended to the liver. The first is the reversibility of rejection. 
Reversal usually requires intensification of treatment, but it has 
sometimes been noted without any change in the pre-existing 
therapy, which suggests that such recoveries had an element of 
spontaneity. Long survival has been achieved in many, and 
possibly even most, patients without complete control of rejec-
tion. The grafts of such patients develop characteristic lesions of 
the intrahepatic portal triads in which the small bile ducts ap-
pear to be selectively and progressively damaged. Small num-
bers of lymphocytes are found in the vicinity of, or lifting up and 
destroying, ductal epithelial cells. This leads to the" disappear-
ing bile duct syndrome." Studies of the antigenicity of the ducts 
and other constituents of liver grafts have demonstrated chang-
ing expression of Class 2 HLA antigens during rejection and 
have demonstrated that the areas of greatest injury are in ves-
sels and ducts where dendritic cells of the macrophage system 
are heavily concentrated. These dendritic cells are important for 
efficient antigen presentation. The practical consequenc;e is that 
patients with slowly rejecting liver grafts can have intrahepatic 
biliary obstruction (with jaundice), arteriopathy, and even graft 
cirrhosis while retaining good synthetic and other functions of 
the hepatocytes.9•10 Such patients eventually become prime 
candidates for late retransplantation. 
GRAFT ACCEPTANCE 
The second observation of overriding practical and theoretic 
interest concerns what has already been referred to as graft 
acceptance. In many of the human kidney and liver recipients 
treated years ago, it was demonstrated that disappearance of 
host resistance to the homograft occurred surprisingly early 
after transplantation, sometimes following an acute rejection 
crisis. This was manifested by eventual declines in the doses of 
immunosuppressive agents necessary to retain stable graft 
function. In many patients, the level of chronic immunosup-
pression has proved to be less than that which at the outset 
failed to prevent the onset of a severe rejection. The ultimate 
step of cessation of all treatment has been too dangerous to 
attempt deliberately, but at least a dozen of the authors' liver 
recipients have for religious, noncompliance, or other reasons 
discontinued all therapy 5 to 10 years ago or longer with no 
subsequent problems. 
The degree to which graft acceptance develops is a prime 
determinant of the long-term prognosis. More than one immu-
nologic pathway may be involved.8•9 One possibility is that 
there is a selective loss of responsiveness to antigens. It might be 
envisioned that specific lymphocyte clones, induced to replicate 
by the graft antigens, are thereby rendered more vulnerable to 
the k.illing effect of immunosuppressive agents than the re-
mainder of the lymphocyte population (Fig. 3). Inasmuch as the 
maintenance of such activated cell lines appears to be thymus-
dependent even in adult life, it is reasonable to be curious about 
the effect of thymectomy as an adjuvant immunosuppressive 
measure. The results of thymectomy in a series of the authors' 
human renal transplants compiled more than 25 years ago were 
inconclusive. 
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Figure 3. Hypothetical mechanisms by which nonspecific immu-
nosuppression may lead to selective abrogation of the host immune 
response. Special susceptibility to these agents of a traction of the 
lymphoid population could lead to exhaustion of a clone and. there-
fore. tolerance. Because maintenance of such cell lines even In adult 
life is apparently thymic-dependent in experimental animals, thymec-
tomy would be expected to aid the process; this appears to be true in 
rodents. but such an effect of thymus removal has not been ~Kfn 
dogS or humans. A possible protective role of immunoglobulin~ 
Macrophage 
Lymphocytes 
••• I •• ~ 
~ ~~ ~ ~---fKKK-orated by the replicating cells is also demonstrated. I':: 
., ... ~ •• * •. IKI"~ •• ~ 
Immune -::= -=.:. -=--_-.::. -=-~~~K{;"~K:";iDy-_-=::I:I-_-_~ 
Suppression ::::::.:. :K-----!;"D-:K:K~~f h ~-=------:::=~ 
_____ -' -..-- - - - - - - ->" - ._fa -.!OJ ______ > 
, I 
The concept of specific. differential tolerance through "clone 
stripping" can partially explain the characteristic cycle of rejec-
tion and reversal occurring after whole organ transplantation 
both in treated animals and in man as well as the weak and 
self-resolving crises in the untreated pig. Moreover. it is consist-
ent with the fact that a wide variety of agents that are capable of 
general immunologic crippling can also provide specificity of 
action under the stipulated conditions of immunosuppressive 
treatment during presence of the antigen. However. classic im-
munologic tolerance cannot be demonstrated in most patients 
who have chronically functiOning whole organ grafts. 
These findings do not disprove tolerance through clonal dele-
tion so much as they suggest that other mechanisms can be 
contributory. One mechanism. termed passive enhancement. has 
been envisioned as a process in which immunoglobins synthe-
sized by the activated lymphoid tissues circulate to the target 
tissue and coat or protect it in some way that is not yet under-
stood (see Fig. 3). The even more ambiguous term active en-
hancement describes a hypothesis that antibodies cause a central 
donor specific immunosuppression of the recipient immune ap-
paratus. 
During the last decade, techniques have been developed 
which allow the detailed identification of cells, cytokines. and 
other components of the immune response. When these 
methods were used in the study of rats that bore permanently 
accepted liver grafts almost a year after discontinuing all immu-
nosuppression. the findings were surprising.s There were no 
alterations of lymphocyte subset distribution, no changes in 
suppressor cells. and no qualitative changes in anti-donor allo-
reactivity as measured in vitro with mixed lymphocyte culture 
techniques and in vivo by skin grafting from the donor species. 
There also was evidence of low level graft-versus-host activity, 
which presumably came from" carrier lymphocytes" still viable 
in the liver grafts. It was as if a symbiotic relationship had been 
established between the host and the graft, each without hazard 
to the other. This was not classic tolerance. 
The hypothesis shown in Figure 3 is multifactorial. The ob-
servations cited above leave open the possibility of changes in 
the graft itself or functions that it performs that decrease its 
vulnerability to rejection. In humans. the macrophage (Kupffer) 
system is replaced entirely by differentiating host monocytes 
within 100 days after transplantation, an alteration that does 
not occur in the vascular endothelial cells or hepatocytes.9 In 
addition. the liver graft permanently secretes significant 
amounts of soluble donor HLA antigens. enough to confer new 
HLA types to the recipient. 1 The role of these events in promot-
ing graft acceptance is speculative. 
Immunoglobulins 
TISSUE TYPING 
ABO blood types of donor and recipient ideally should be the 
same; failing this, they should be compatible (example: 0 to A). 
In kidney transplantation. standard HLA typing has not been a 
precise method of selecting biologically suitable cadaveric 
donors. Even if these techniques were more reliable as an in-
strument of donor selection. it is unlikely that seeking well-
matched livers would be possible. The need for transplantation 
has been so pressing in appropriate candidates that it often has 
been obligatory to proceed with the first available organ. Thus. 
most of the matches for liver transplantation worldwide have 
been poor ones. Puzzling reports have been published from two 
large centers (Pittsburgh and Cambridge) that survival after 
liver transplantation is actually inversely related to the quality 
of HLA matching. 10 This would be such a violation of an impor-
tant biologic principle that much verifying data are required 
before indulging in speculation about what may prove to be a 
sampling error. 
PROCUREMENT AND PRESERVATION 
OF ORGANS 
In contrast to typing, the procurement of a fresh. functioning, 
nonischemic liver is of paramount advantage. Unquestionably, 
one of the most important advances that has been made in 
transplantation has been social in nature. i.e .• acceptance by the 
public of the concept of cadaveric organ removal. The interval 
of normothermic ischemic injury was nearly eliminated. since 
the organ usually could be dissected free in the presence of an 
intact and effective circulation. Suitable donors usually are vic-
tims of head trauma or of asphyxia that has caused brain death. 
During the last few years, the need for the procurement of 
multiple organs from the same donor has sharply increased. 
Exclusive of the pancreas, the most common combinations have 
been kidneys and liver; kidneys, liver, and heart; and kidneys 
and heart. in that order. Techniques have been developed that 
permit such removal without jeopardy to any of the individual 
grafts. The guiding principle is avoidance of warm ischemia in 
all organs. This is achieved by carefully timed and controlled in 
situ infusion of cold solutions into anatomic regions. the limits 
of which are defined by preliminary dissection.12 
Until late 1987, the safe outer limit for human liver preserva-
tion was set at 6 or 8 hours. The Cambridge-King's College team 
in England and many European teams had used a plasma solu-
tion for cold infusion of the homografts. The alternative was a 
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preservation fluid (Collin's solution) with a composition similar 
to that found in cells. In dogs, the two approaches yielded com-
parable results. These techniques pennitted the shipment of 
livers from city to city. It was learned that excessive ischemia or 
bile left within the ducts could cause autolysis and facilitated 
delayed mucosal sloughing and cast formation. 
The situation was dramatically improved with the introduc-
tion by Belzer, Jamieson, and Kalayoglu of the University of 
Wisconsin (UW) solution.u Although this solution has more 
than a dozen constituents, the essential ingredients are thought 
to be two sugars, lactobionate and raffinose, which are imper-
meants that prevent water imbibition by the cells. In addition to 
protecting the hepatocytes, there is much evidence that the mi-
crovasculature also is benefited. After perfusioii.JV,ith UW solu-
tion, cadaveric human livers can be stored saf~y for at least 18 
hours. Beyond this time, there is a slowly incre"ing incidence of 
primary nonfunction, which reaches unacceptable levels after 
24 hours.16 
The gains in the effectiveness of organ procurement and dis-
tribution made possible by the UW solution have been large. All 
parts of North America have been placed within the range of all 
others. Even intercontinental sharing is now practical although 
infrequently practiced. Even with short periods of preservation, 
the quality of grafts is better when they are preserved with the 
UW solution versus the Collin's solutions, and the incidence of 
hepatic artery thrombosis is reduced. The UW solution is 
thought to be a generic advance applicable to all solid organs. 
The next step in liver preservation probably is continuous 
perfusion techniques, using either blood or asanguineous 
fluids. This approach was demonstrated to be feasible more 
than 20 years ago, but the equipment was too cumbersome to be 
practical. 
SURGICAL TECHNIQUES OF ORTHOTOPIC 
TRANSPLANTATION 
THE BYPASS QUESTION. With removal of the host liver, it 
is necessary to temporarily cross-damp the great veins draining 
the intestines (portal vein) and the lower half of the body (infe-
rior vena cava). Dogs die promptly if the distal venous pools are 
not decompressed. In contrast, humans with liver disease often 
have tolerated this venous obstruction surprisingly well. The 
tolerance to portal and inferior vena caval cross-damping was 
explained by man's inherently richer network of potential col-
lateral channels for the return of blood to the right heart and by 
the presumed increase in the size and ramifications of these 
veins in consequence of the underlying liver disease. The au-
thors were able to develop liver transplantation to an acceptable 
service level without decompressing the obstructed venous sys-
tems, and some surgeons continue to believe that this expedient 
usually is unnecessary. 
However, the fact that most patients can recover from portal 
and inferior vena caval cross-damping created a false impres-
sion about the safety of this practice. Venous hypertension of 
the obstructed venous beds contributes significantly to the 
bleeding of the anhepatic phase. Usually, there is gross swelling 
of the intestine during the period of occlusion. Subsequently, 
many patients suffer from third space fluid sequestration and 
postoperative renal failure. 
The extent to which these complex physiologic events can 
contribute to the high perioperative mortality has become in-
creasingly evident. The authors now perform venous bypasses 
in all adults and in most children weighing more than 15 kg. 
Cannulas are placed into the inferior vena cava through an iliac 
or femoral vein and into the portal system through the open end 
of the transected portal vein. During the anhepatic phase, the 
blood is pumped to a large vein in the neck or arm with equip-
ment that does not require total body heparinization (Fig. 4). 
Common bile ""ef--~1gir 
duct 
IntrahepatiC g~~~~~f!!!f" 
I.V.C. 
FIgure 4. Venovenous bypass developed for use during the anhepatiC phase of 
liver transplantation during which the new liver is connected to recipient vessels. By 
using coagulation-resistant tubing and an atraumatic pump. it has been posSible to 
bypass large vOlumes of blood Without using any heparin. The venovenous bypass 
has a revOlutionary effect on the ease of liver transplantation in adults. (From 
Griffith, B. P,. Shaw. B, W .• Jr .• Hardesty. R. L., etat.: Veno-venous bypass without 
systemic anticoagulation for transplantation of the human liver. Surg. Gynecot. 
Obste!.. 160:270. 1985,) 
The safety of liver transplantation in adults has been greatly 
improved with this technique. 
HEMORRHAGE 
Other problems during and after operation may be caused by 
derangements in the coagulation mechanism, which may lead 
to hemorrhage or thrombosis. The nature of the underlying 
hepatic patholOgiC process produces portal hypertension in 
nearly every patient, and the nature of the operation tends to 
exaggerate it if bypasses are not used. The usual consequence is 
mechanical bleeding that in some cases can assume fonnidable 
proportions during the procedure. Many of the normal coagula-
tion factors that might help control hemorrhage are dependent 
on the liver and are therefore defective. In addition, fibrinolysis 
can cause or complicate the coagulopathy in many cases. If the 
homograft does not function properly, hemostasis may be im-
possible to achieve. 
When hemorrhage occurs, the surgeon's challenge is to use all 
available hemostatic tactics-ligatures, sutures, and cautery-
until the revascu1arized homograft can participate in what is 
hoped is appropriate coagulation function. If hemorrhage can-
not be controlled, fresh frozen plasma, platelets, and an-
tithrombolytic agents such as E-aminocaproic acid (EACA) may 
be required. With earlier patients, whose homografts were often 
of less than optimal quality, an attempt was made to treat bleed-
ing problems by administering massive amounts of thrombo-
genic agents. However, hypercoagulability was caused in some 
instances with consequent thrombosis of the graft vessels. Ironi-
cally, the better the condition of the recipient and of the grafts, 
the greater the risk of unwanted coagulation if clot promoting 
therapy is used. Almost every series of liver transplants has had 
examples of thrombosis. Effective management of coagulation 
has been a special contribution of the anesthesiologists. 7 
AIR EMBOLI AND NEUROLOGIC DAMAGE 
Eventually lethal neurolOgic invalidism was observed in 9 of 
the first 98 patients undergoing liver replacement. The compli-
cations occurred during or shortly after operation. Several of 
these patients awakened from anesthesia but then had a sec-
ondary decrease in consciousness, seizures, and other crippling 
abnormalities, including brain stem syndromes such as akinetic 
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mutism. They died within a few days to 2 months. It ultimately 
was realized that air emboli from the homografts were responsi-
ble for some, although not all, of these cerebral or brain stem 
catastrophes.13 The ease with which air passed to the systemic 
circulation was explicable by the right-to-left venous-arterial 
shunts that are common in chronic liver disease. Air released 
into the pulmonary circulation apparently passed through these 
collaterals to the systemic circulation, including the arterial sup-
ply to the brain. 
With the delineation of this cause for the neurologic compli-
cations, measures were instituted to prevent it. During revascu-
larization of the liver, electrolyte solution was slowly infused 
through a portal vein cannula. While the vena~al anasto-
moses were performed, air bubbles could escape f the graft 
vessels before a blood supply was restored (Fig. ). Since the 
institution of this simple preventive measure, th incidence of 
neurologic complications has been reduced. 
However, despite all efforts, neurologic complications can 
destroy an apparently perfect liver transplantation because of 
pre-existing abnormalities in the brain that can be the basis for 
perioperative or postoperative tragedies. Pathologic changes 
can almost always be found in the central nervous system of 
nontransplant patients who die of chronic liver disease. These 
include Alzheimer (proliferative) changes in the glial tissue, de-
pletion of the myelin in the pons (central pontine myelinolysis) 
or elsewhere in the brain stem or higher brain (extrapontine 
myelinolysis), cortical atrophy, and edema. Alzheimer changes 
and central pontine myelinolysis can be produced reliably in 
rats and subhuman primates by portacaval shunt even though 
the animals appear well clinically. More recently, a role of peri-
operative hypernatremia in aggravating such lesions has been 
suggested. 
VASCULAR ANOMALIES 
In planning liver transplantation, the surgeon must be pre-
pared for a high incidence of anatomic variations in either the 
graft or the host structures. These have been encountered in 
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Figure 5. Technique to prevent air embolism from orthotopic liver homogratts. 
A. Continuous perfusion of solution through the portal vein as vena caval anasto-
moses are constructed. B and C. Escape of air bubbles as the anastomoses are 
completed. (From Starzl. T. E .• et aI.: Acute neurological complications after liver 
transplantation with particular referenca to intraoperative air embolus. Ann. Surg .• 
187:236. 1978.) 
almost 40 per cent of the authors' patients. Multiple arteries 
have been the most frequent anomalies. If these are in the 
donor, the guiding principle is to convert these by back table 
anastomoses to a single vessel for anastomosis to a single recipi-
ent vessel (Fig. 6). If there are multiple recipient vessels, it may 
be possible to dissect back to a common trunk, or even to the 
celiac axis, for an anastomotic site. However, the best solution 
may be to place a donor iliac graft, which should always be 
brought back with the liver, from the infrarenal recipient aorta 
into the hilum (Fig. 7). 
Thrombosis of the portal vein was formerly thought to be a 
contraindication to orthotopic liver transplantation. All that is 
necessary in such cases is to find an open segment in the supe-
rior mesenteric vein and to interpose a segment of donor iliac 
vein into the hilum. The vein graft is passed anterior to the 
pancreas and beneath the pylorus (Fig. 8). Retrieving a liver 
without the iliac artery and vein grafts may be responsible for 
the recipient's death, since the need for these vascular grafts is 
sometimes completely unexpected.. 
BILIARY TRACT PROBLEMS 
Obstruction or bile fistula formation leads to repeated bacte-
rial contamination, with resulting cholangitis and consequent 
systemic infection. An acceptable method of biliary reconstruc-
tion is choledochocholedochostomy, using aT-tube stent (see 
Fig. 1, inset) that is left in place for about 2 months. After the 
T -tube is removed, periodic retrograde cholangiography via the 
duodenum can be performed in such recipients. 
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Figure 6. A. A common anomaly in which a right hepatic artery originates from 
the superior mesenteric artery. This right artery always is posterior to the portal 
vein. B. With the anomaly shown inA. the splenic artery can be anastomosed to the 
anomalous right hepatic artery. thereby converting the origin of the blood supply to 
a single vessel based on the celiac axis. 
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Figure 7. An antepancreatic route for a vascular graft plaoed onto the infrarenal 
abdominal aorta. The graft is brought either to the right or left of the middle COlic 
vessels, anterior to the pancreas, and beneath the pylorus. Note the homograft 
anomaly in which a right, middle and left hepatic anery arise separately from the 
donor aorta. All three vessels were included in a Carrel patch, which was anasto-
mosed as a cap onto the end of the iliac artery graft. (From Tzakis, A. G., T odo, 5 .• 
and Starzl. T. E.: The arterial route for arterial graft in liver tranSplantation. Transpi. 
Int., 2:121, 1989.) 
Choledochocholedochostomy often is not feasible, as for ex-
ample in children with biliary atresia. Choledochojejunostomy 
(Fig. 1) to a Roux limb of jejunum is a highly satisfactory option 
and should be chosen if there is the slightest question about the 
quality of duct-to-duct repair. 
With the simple techniques demonstrated in Figure 1, the 
descriptive term Achilles heel of liver transplantation, which for-
merly was applied to biliary tract reconstruction, no longer per-
tains. Nevertheless, the pOSSibility of duct obstruction must be 
entertained in the postoperative management of liver trans-
Figure 8. The use of antepancreatic iliac vein graft from the superior mesenteric 
vein circumvents portal vein thrombosis as a contraindication to tranSplantation, 
providing a good superior mesenteric vein is still open. (From Tzakis. A. G .• Todo, 
S., Stieber, A., and StarzI, T. E.: Venous jump grafts in patients with portal vein 
thrombosis. Transplantation, 48:530, 1989.) 
plantation whatever the method of reconstruction. Until the last 
few years, postoperative hepatic dysfunction was too readily 
ascribed to rejection, when, in fact, obstruction or cholangitis, or 
both, was frequently responsible. Even in the absence of a bili-
ary tract problem, rejection may not be responsible. Hepatitis 
associated with hepatitis B surface antigen (HBsAg), cytomega-
lovirus (CMV), C virus, and other viruses has been observed as 
well as drug toxicity. 10 At the present time, the development of 
jaundice after transplantation is a signal for cholangiography 
and usually for liver biopsy. The histopathologic findings in the 
biopsy tissue may not provide an unequivocal answer. Then, 
the diagnosis of rejection must be made by exclusion. 
ANESTHESIA 
During operation there are metabolic abnormalities other 
than those concerned with coagulation that contribute to the 
complexity of anesthetic management. Not only is the proce-
dure long and difficult, but, even more important, it is an opera-
tion on the primary organ involved in the metabolism and de-
toxification of most common anesthetics. At any point during 
the operation, the liver is inherently impaired, absent, or untried 
in its new setting. Therefore, the task of the anesthesiologist is to 
correctly administer pharmacologic agents that, first, are not 
hepatotoxic and, second, do not depend primarily on the liver 
for their degradation. In the authors' early cases, reliance was 
placed primarily on combinations of volatile agents in nonex-
plosive concentrations. Such management permitted use of 
electrocautery, gave flexibility in lightening or deepening anes-
thesia, and allowed anesthesia to be abruptly discontinued if 
required by changing physiologic circumstances. Recently, less 
effort has been made to use volatile anesthetics. 
IMMUNOSUPPRESSION 
The immunosuppressive regimens used and the year of their 
first clinical applications are summarized in Table 1. The move-
ment through the years was toward increasing specificity of the 
immunologic target, culminating in the introduction of cyclo-
sporine. The use of cyclosporine with steroids, and later the use 
of these two drugs with azathioprine and antilymphoid globu-
lins, had an immediate impact on the transplantation of all 
organs, but especially of the liver.s The I-year patient survival, 
which had been approximately 35 per cent before 1980, dou-
bled (Fig. 9) or, in the case of low-risk patients, nearly tripled. 
During the 1980s transplantation developed as a highly de-
fined multidisciplinary special branch of medicine. In addition 
to the impetus provided by cyclosporine, the improvements in 
organ storage and the establishment of organ distribution sys-
tems that linked all parts of the United States and Canada were 
crucial pragmatic improvements. 
Collateral developments in an understanding of the mecha-
nisms of rejection and better understanding of how these are 
effected by immunosuppression have facilitated what may be 
even more important advances during the next decade. Cyclo-
sporine inhibits the activation of T lymphocytes and depresses 
the production and expression of multiple cytokines of which 
interleukin-2 andinterferon-y have been most extensively stud-
ied.s The cyclosporine binding site is a low-molecular-weight 
cytosolic protein (cyclophilin) that is probably only one of a 
family of binding sites that participate in a broad range of physi-
ologic effects. 
It was realized at the outset that nephrotoxicity was the prin-
cipal and dose-limiting side effect of cyclosporine; even when 
serum creatinine remains normal, hypertenSion and decreases 
in glomerular filtration occur. The remarkable spectrum of cy-
dosporine's actions can be demonstrated by other side effects, 
including gingival hyperplasia and hirsutism. Subtle changes in 
carbohydrate metabolism occur. Insulin secretion by the pan-
creatic islets is depressed with increased peripheral insulin re-
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TABLE 1. Immunosuppressive Drug Regimens Used Clinically for Whole-Organ Transplantation 
Year Described 
Agents and Reported 
Azathioprine 1962 
Azathioprine, steroids 1963 
ALG as adjunct to 2 1966 
Cyclophosphamide substitute 
for azathioprine 1970 
Place 
Boston 
Denver 
Denver 
Denver 
Ineffective, dangerous 
Suboptimal 
Deficiencies 
High incidence of infection 
Cyclosporine 1978-1979 Cambridge 
No advantage except for patients with azathioprine toxicity 
Suboptimal 
Cyclosporine, steroids with or 
without other adjuncts- 1980 
Monoclonal OI<T3 1981 
FK 506, steroids 1989 
Denver 
K~K~ Boston 
,'. Pittsburgh 
Nephrotoxicity limits dose: rejection not always controlled 
High incidence of infection 
Being evaluated 
-Lymphoid depletion with thoracic duct drainage, anti! I.' hocyte globulin (ALG), OKT3, and/or azathioprine. 
sistance. Other metabolic changes caused by cyclosporine 
include hypercholesterolemia and hyperuricacidemia. In 
addition, neurotoxicity is a pervasive finding in almost all pa-
tients, Although serious neurotoxicity occurs in about 20 per 
cent of patients, more subtle manifestations are trembling, sen-
sitivity to light, paresthesias, mood changes, and insomnia. 
These manifold effects of cyclosporine were not completely 
recognized until after more than 10 years of clinical use. It was 
assumed that the side effects of cyclosporine were largely idio-
syncratic and not related to the desired effects on the immune 
system. The possibility that this may be an incorrect assumption 
has been raised by clinical observations with another agent 
called FK 506, which has a molecular structure completely dif-
ferent from that of cyclosporine,l1 Its binding site is distinct 
from cyclophilin, without cross-immunoreactivity to specific 
monoclonal antibodies, although both drugs have a cis-trans 
peptidyl-prolyl isomerase backbone. 
Weight for weight, FK 506 is 100 times or more potent than 
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Figure 9. Actuarial (life-table method) patient survival rates for different age 
groups after liver transplantatiOn under cyclosporine and Iow-dose prednisone. 
Based on 1565 patients receiving liver transplants at the University of Pittsburgh 
between 1981 and 1989. 
cyclosporine. Insofar as it has been determined, its effect on the 
lymphocyte population and cytokines is similar to, if not identi-
cal to, that of cyclosporine. The side effects are similar to those 
of cyclosporine, although there are important differences. FK 
506 is less nephrotoxic, does not cause hypertension, causes a 
decline instead of an increase in cholesterol, and does not pro-
duce gingival hyperplasia. Instead of causing hirsutism, FK 506 
may even cause hair loss. Thus, these two drugs affect the same 
clinically significant end points, but not to the same extent and 
sometimes not even in the same direction. 
The molecular basis for these effects is not known, An un-
likely possibility is that there is immune modulation of the di-
verse functions that are affected. Far more likely is an effect on 
secondary messenger systems, including but not limited to pep-
tidyl-prolyl isomerase, which could modulate the amount or 
expression of hormones and other biologically active com-
pounds. A better understanding of such details could provide a 
pathway for searching for other immunosuppressive drugs. 
In the meanwhile, extensive clinical trials with FK 506 have 
been initiated in the United States and Europe. At the Univer-
sity of Pittsburgh, more than 350 patients have been adminis-
tered this drug for primary therapy or for the rescue of failing 
liver grafts under cyclosporine regimens. 
COMPLICATIONS OF IMMUNOSUPPRESSION 
RISKS WITH ALL ORGANS. The most obvious penalty of a 
depressed immune system is heightened susceptibility to infec-
tion. It has also become obvious that chrOnically immunosup-
pressed patients have an increased vulnerability to de novo ma-
lignancies. This complication is presumably due to failure of the 
depressed immunologic surveillance mechanisms to identify 
the tumor tissues as alien and to eliminate them or restrict their 
growth. 
EXTRA RISKS FOR LIVER RECIPIENTS. There are some 
special risks for the candidate for liver transplantation. One is 
the fact that hepatic injury in all types of organ recipients has 
commonly been produced by the agents, individually orin com-
bination, of the therapeutic regimen. In some instances, viral 
hepatitis, apparently made chronic by the partial immunologic 
invalidism of the host, has been a plausible explanation. Lethal 
hepatitis due to adenovirus, cytomegalovirus, and herpes sim-
plex and herpes zoster viruses has been recorded.10 In other 
patients, hepatotoxicity of the drugs was probably responsible. 
With liver malfunction, dose control of some of the agents may 
become difficult, since the liver participates in their pathways of 
action or degradation. These hepatic factors are obviously im-
portant in any situation requiring immunosuppression, but they 
have heightened significance for a traumatized liver trans-
planted to a new and hostile environment. 
In the liver recipient, postoperative bacterial sepsis of the 
graft itself has proved to be a special problem, undoubtedly in 
---K~K----- .. --.---
430 TRANSPLANTATION 
part because of the anatomic location of the orthotopically 
placed organ interposed between the intestinal tract and the 
heart. Bacteria from the bowel, particularly of the gram-nega-
tive type, can be brought into contact with the transplanted liver 
via the intestinal veins draining into the portal vein or, far more 
important, by retrograde spread up the duct system after pas-
sage through the biliary anastomosis. In either event, the pres-
ence of nonviable hepatic tissues provides a perfect medium for 
bacterial growth. Eventually, abscesses or partial gangrene of 
the transplant can occur, with characteristic unvisualized areas 
of liver scans, gram-negative bacteremia, and all the findings of 
generalized sepsiS. 
AVOIDANCE OF HOMOGRAFT SEPSIS. Antibiotics are 
administered intraoperatively for the first several postqperative 
days. The authors' prophylactic protocol includes ag~ts effec-
tive against gram-negative bacteria. The most impoJ:1;ant surgi-
cal technical step in reducing homograft sepsis has ~een to use 
biliary reconstructive techniques that prevent systematic con-
tamination by gastrointestinal contents (see Fig. 1). All such 
efforts are futile if rejection with consequent tissue necrosis is 
allowed to occur. The paradox is that the immunosuppressive 
agents that weaken natural immune defenses against infection 
must be considered the foremost weapon in maintaining the 
tissue barrier against infection. 
Until 1980, infection was the primary, or an important. con-
tributory cause of most deaths. Moreover, the development of 
almost any type of intra-abdominal or intrathoracic complica-
tion could lead quickly to untreatable sepsis. The situation was 
dramatically improved when therapy with cyclosporine and 
low doses of prednisone was introduced in early 1980. The 
relative ease with which infections could now be controlled 
while preventing irreversible rejection was responsible for the 
improved results. In addition, the antiviral agents acyclovir and 
gancyclovir became available to treat or prevent infections by 
viruses of the herpes family, including, above all, CMV. 
INDICATIONS FOR LIVER REPLACEMENT 
Liver transplantation is being performed for a wide variety of 
indications. Under cyclosporinejsteroid-based immunosup-
pression, over 1500 patients have received liver transplants 
since the program transferred from the University of Colorado 
to the University of Pittsburgh in 1981. High survival rates have 
been achieved, even in higher-risk patients such as infants and 
adults over the age of 60 (see Fig. 9). 
INFANTS AND CHILDREN. The most common cause of 
conjugated hyperbilirubinemia persisting beyond the first 2 
weeks of life is congenital biliary atresia, and more than half of 
the liver transplantations performed in infants are done for this 
indication. Portal decompression by portoenterostomy (Kasai 
operation) is possible in 20 to 30 per cent of patients but must be 
performed within 60 to 90 days after birth to be successful. Even 
with a successful Kasai operation, biliary cirrhosis is nearly cer-
tain to develop later in life. Recurrent cholangitis is the most 
common late complication after a Kasai operation. Although 
successful portoenterostomy can gain valuable time and permit 
growth of the patient, the possibility of making transplantation 
the first operation for biliary atresia has been discussed more 
openly in recent years now that techniques have been devel-
oped for using partial liver fragments from larger donors. If 
Kasai operations are used, it is important to avoid reoperation 
after an initial portoenterostomy, because these are usually 
fruitless, except for repair of minor technical faults or for relief 
of obstructions due to biliary stones. Multiple operations can 
seriously jeopardize a subsequent transplant procedure. Neo-
natal (giant cell) hepatitis is another important but much less 
common cause of persistent jaundice in infants. It is also an 
excellent indication for liver transplantation. 
Liver transplantation in children has also been performed in 
patients with a wide variety of inherited inborn errors of metab-
olism such as alphal-antitrypsin deficiency, tyrosinemia, glyco-
gen storage disease, Type II familial hypercholesterolemia (FH), 
protein-C deficiency, and some forms of hemophilia. The 
growing list of inborn errors which can be palliated with liver 
transplantation is given elsewhere. lo The first survivor of a si-
multaneous heart-liver transplant was a 6-year-old child with 
FH who had a normal-appearing liver but had devastating coro-
nary artery disease caused by a metabolic abnormality based in 
the liver. Replacement of a normal-appearing liver from this 
nonjaundiced child was necessary to prevent recurrence of dis-
ease in the transplanted heart. 
Patients with inborn errors should undergo liver transplanta-
tion before developing irreversible sequelae such as neurolOgiC 
injury (Wilson's disease, urea cycle enzyme deficiency), ad-
vanced pulmonary disease (alphacantitrypsin deficiency), or 
hepatocellular cancer (tyrosinemia). In many of these disorders, 
the genetic defect is well understood, and cure by liver trans-
plantation can be anticipated. For example, patients with 
alpha\-antitrypsin deficiency assume the Pi (protease inhibitor) 
type of their donors and the low serum values of the deficient 
alpha globulin are promptly and permanently restored to nor-
mal. The abnormal amino acid pattern characteristic of tyro-
sinemia is almost completely rectified within hours. The same 
holds true for the aberrations caused by Type I glycogen storage 
disease (glucose-6-phosphatase deficiency), as exemplified by 
the ability of these patients to fast for 1 or 2 days after transplan-
tation without the hypoglycemia that previously occurs within 
hours. Some of these inborn errors are known to be caused by a 
specific enzyme deficiency, whereas the pathogenesis of others, 
such as Wilson's disease, is not understood. Nevertheless, liver 
transplantation appears to be equally effective in the treatment 
of Wilson's disease, and recurrence has not been demonstrated 
for as long as 18 years after liver transplantation. 
Other indications for liver transplantation in children have 
included postnecrotic cirrhosis, familial cholestasis, fulminant 
hepatic failure (viral or drug induced), secondary biliary cirrho-
sis, Budd-Chiari syndrome, and primary hepatobiliary cancers. 
As in adults, there is a high recurrence rate after liver transplan-
tation for most hepatocellular or bile duct cancers. However, 
long-term survival has been achieved after liver transplantation 
for hepatoblastoma. 
ADULTS. The most common indication for liver transplanta-
tion in adults is postnecrotic cirrhosis. Most of these patients 
have cryptogenic cirrhosis or non-A, non-B chronic aggressive 
hepatitis (hepatitis C). The true incidence of hepatitis C in this 
population is not yet known, but will become better defined in 
the next few years with the introduction of a specific test for 
detecting serum antibody to this agent. Also, it should be possi-
ble to determine the risk of reinfection with hepatitis C after 
liver transplantation. 
In some regions of the third world, infection with the hepati-
tis B virus (HBV) is endemic and is the most common cause of 
advanced liver disease. It is also associated with an increased 
incidence of hepatoma. Recurrence of infection in HBsAg+ pa-
tients after liver transplantation is high. More than 80 per cent 
of such patients remain carriers after transplantation, but the 
frequency and severity of reinfection is unpredictable and can 
be well tolerated by a significant proportion of patients. Al-
though efforts to reduce the incidence and severity of reinfec-
tion with interferon and active and passive immunization have 
been disappointing, the value of transplantation has not been 
vitiated. 
Alcoholic cirrhosis, the most common cause of chronic liver 
failure in Western society, has been a controversial indication 
for liver transplantation because of the social stigmata asso-
ciated with the disease, fear of recidivism, and the poor medical 
condition of many of these patients. However, recent experi-
ence with a series of over 100 patients receiving liver transplants 
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for this disease at the University of Pittsburgh has demonstrated 
excellent survival rates with follow-up to 4 years. Behavior 
modification through participation in a rehabilitation program 
for chemical dependency is an important part of the postopera-
tive care of these patients. 
Cholestatic liver diseases, including primary biliary cirrhosis 
and primary sclerosing cholangitis, are excellent indications for 
liver replacement. Previous surgical forays into the hepatic 
hilum in patients with sclerosing cholangitis can complicate 
eventual liver transplantation; and as a consequence, these 
operations are no longer employed. 
Both before and after the introduction of cyclosporine, efforts 
were made to utilize liver transplantation for patie~ with pri-
mary hepatic malignancies that could not be manageptby subto-
tal hepatic resection. Although some patients have-had pro-
longed periods of effective palliation, recurren~ of tumor 
within 3 to 18 months of transplantation is common and has 
limited the effectiveness of this approach. More radical opera-
tions, including the upper abdominal exenterations, in addition 
to transplantation and aggressive adjuvant chemotherapy are 
currently under investigation. 
Fulminant hepatic failure may require emergency liver trans-
plantation. It is unusual for patients with hepatitis A to require 
liver transplantation. Many patients with acute acetaminophen 
intoxication can recover despite alarming abnormalities of hep-
atocellular enzymes and prothrombin time. ApprOximately 40 
per cent of patients with fulminant HBV infection recover with 
skilled medical care. However, it may be necessary to explore 
some of these patients with a new liver available and to deter-
mine by intraoperative biopsy of the native liver whether or not 
liver replacement is advisable. Fulminant non-A, non-B hepati-
tis has a poor prognosis, and liver transplantation is an impor-
tant consideration early in the management of patients with this 
disease. 
Regardless of etiology, the prognosis after liver transplanta-
tion for fulminant hepatic failure is influenced by renal failure, 
metabolic acidosis, and central nervous system deterioration. 
Early consultation with a liver transplant program is an impor-
tant part of the modem management of the patient with fulmi-
nant hepatic failure. 
As in children, there are many other conditions for which 
liver transplantation has been successfully performed in adults, 
including, but not limited to, congenital hepatic fibrosis, inborn 
errors of metabolism, Budd-Chiari syndrome, secondary biliary 
cirrhosis, massive hepatic trauma, cystic fibrosis, and polycystic 
liver disease. 
RESULTS AND COMPLICATIONS 
Improvements in operative technique and the routine use of 
the venovenous bypass in adults and large children have re-
duced intraoperative mortality to less than 1 per cent and peri-
operative (30-day) mortality to under 10 per cent for most 
groups of patients. 
The life-table survival rates for major diagnostic groups after 
liver transplantation under cyclosporine and prednisone in 
1565 patients atthe University of Pittsburgh between 1981 and 
1989 are summarized in Figure 10. Most of the mortality occurs 
within the first 6 months after transplantation. After transplan-
tation for cholestatic liver disease, chronic active hepatitis (ex-
cept HBsAg+), and alcoholic cirrhosis, I-year patient survival is 
near 80 per cent and remains above 70 per cent or better at 5 
years. Similar survival rates are seen after liver transplantation 
for most other causes of norunalignant chronic liver disease. 
Despite the significant risk of recurrent infection, survival at 5 
years after liver transplantation for HBsAg+ cirrhosis is 50 per 
cent. Significant salvage has also been achieved for fulminant 
hepatic failure, and this may improve further with more aggres-
sive referral of patients to transplant centers before irreversible 
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Figure 10. Actuarial (life-table method) survival rates after liver transplantation 
for major diagnostic ctasses. HBsAg + cirrhosis = end stage cirrhosis in patients 
positive for the hepatitis B surface antigen. Based on 1565 patients receiving liver 
transplants at the UniverSity of Pittsburgh between 1981 and 1989. 
medical complications occur. The poor long-term survival after 
transplantation for primary tumors reflects the high rate of re-
current disease for most tumors. 
ApprOximately 20 per cent of patients require one or more 
retransplantations for primary graft nonfunction, rejection, 
technical complications (most often hepatic artery thrombosis), 
infections (viral hepatitis), or recurrent disease. Approximately 
8 per cent of grafts fail to function within the first few days after 
transplantation. Some of these failures may be mediated by 
immunologic events that have yet to be completely delineated, 
and others are failures of preservation. Survival after retrans-
plantation for chronic rejection is over 70 per cent. The outcome 
after retransplantation for technical failure or recurrent disease 
is dependent upon etiology. 
Hepatic arterial thrombosis may cause acute hepatic gan-
grene; biliary tract necrosis with hepatic abscess formation; or 
relatively asymptomatic bacteremia, which may respond well to 
intravenous antibiotic therapy. Dearterialization must be sus-
pected in any patient with fever and gram-negative sepsis or a 
biliary leak after liver transplantation. Because of the variable 
clinical presentation, not all patients require early retransplan-
tation, and a few have not required it at all. However, the major-
ity of patients who do not develop hepatic necrosis or abscess 
eventually develop intrahepatic biliary strictures that necessi-
tate replacement of the graft. 
Portal vein and vena caval thrombosis after liver transplanta-
tion are both uncommon but usually require replacement of the 
graft. Some patients with late portal vein thrombosis have been 
managed by performing distal splenorenal shunts. Biliary tract 
complications have been previously discussed. Ampullary dys-
function with generalized dilatation of the biliary system is the 
most frequent complication after duct-to-duct reconstruction 
over aT-tube stent. It is best treated by revision to a Roux-en-Y 
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The FK 506 results were in 76 patients treated during Phase 1 Clinical trials of FK 
506. conducted at the University of Pittsburgh during 1989. compared with the 
historical experience With cyctosponne from 1981 to 1989. . 
choledochojejunostomy, although some centers have managed 
this complication by endoscopic papillotomy. 
The most common cause of death after liver transplantation is 
infection complicating immunosuppressive therapy. Sulfa-
zoxasole-trimethoprim (Bactrim) prophylaxis has dramatically 
reduced the incidence of Pneumocystis carinii pneumonia in 
transplant recipients. Treatment with gancyclovir has also 
significantly reduced the morbidity and mortality of posttrans-
plantation CMV infections. 
With the use of FK 506, the early death rate after liver trans-
plantation may have been influenced favorably. In Figure 11 is 
shown the 3-month survival after primary transplantation 
under FK 506/steroid treatment versus the historical record 
with the use of cyclosporine regimens. These hopeful but pre-
liminary observations require extension, as well as confirmation 
by other workers. 
AUXILIARY LIVER TRANSPLANTATION 
The alternative to hepatic replacement is to leave the native 
liver in place and to transplant an extra liver that is in some 
ectopic site, such as the splenic bed, the right or left paraverte-
bral gutter, or the pelvis. The main theoretic advantage of auxil-
iary transplantation is that the recipient is not at the outset 
placed totally at the mercy of homograft function. A second 
possible advantage would be avoidance of the technical hazards 
of recipient hepatectomy. 
The provision of splanchniC venous inflow is critical for opti-
mal graft function because this blood contains "hepatotrophic 
factors" of which insulin is the most important. I .. The condition 
of providing a splanchnic venous inflow to the auxiliary graft 
has been met in almost all clinical trials, which by 1978 num-
bered more than 50.2 
Auxiliary liver transplantation with real prolongation of life 
was first achieved at the New York Memorial Hospital on De-
cember 13, 1972.% The recipient, who had biliary atresia, is still 
alive more than 16 years later (personal communication, J. C. 
Fortner, April 1989). In 1980, a 29-month survival of an adult 
was reported from Paris. The patient, who had hepatitis B, died 
of a hepatocellular carcinoma in his host liver 8 years after 
transplantation (personal communication, H. Bismuth, January 
1989). 
With the increased success of orthotopic liver transplantation, 
interest in auxiliary transplantation waned. However, there has 
been a recent report of the transplantation of whole livers or 
liver fragments to the right paravertebral gutter of six adult 
recipients, by essentially the same operation as that tried ear-
lier. Is At the time of reporting, with follow-up of 5 to 23 months, 
all six recipients were alive. Cautious further trials undoubtedly 
can be expected. 
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Caine, R. Y. (Ed.): Uver Transplantation: The Cambridge-King's College Hospital 
Experience, 2nd ed. Orlando, Grone &: Stratton, 1987. pp. 1-571. 
This text is an updated account of what now is a 20-year experience with liver 
transplantation at Cambridge Unit/ersity and King's College Hospital, London. It 
summarizes briefly what has been accomplished in other centers as well. and 
annotates the wide-ranging basic and clinically oriented animal and bench re-
search that has been a collllteral theme throughout the entire time. The book 
prot/ides information on the specific topiC of liver transplantation that no new 
group can afford to ignore. More important. it provides insight into the intellectual 
processes of CaIne, who ranks as one of the supreme surgeon-scientists of this or 
any era. Cyclosporine was introduced into clinical medicine by Caine, and the 
consequences of this major contribution can be traced through the pages of his 
boole. 
Kahan, B. D.: Cyclosporine. N. Engl. J. Med., 321:1725,1989. 
This scholarly account summarizes the world experience with eyclosponne over 
the first 10 years of its use. Although it is not specifically conamed with liver 
transplantation, all of the information is relet/ant. There has bun no better de-
scription of the fundamental mechanisms of eye/osporine. its therapeutic powers, 
and its side effects. 
Maddrey, W. C. (Ed.): Transplantation of the liver. New York, Elsevier, 1988. pp. 
1-352. 
The collection of chapters including contributions from experienced guest authors 
was largely an exercise of preparation for the addition of liver transplantation to 
the treatment armamentarium at the hepatology center at Thomas /efferson Uni-
versity, Philadelphia. The perspective of the text was therefore different from the 
other recommended texts. The value of Maddrey's approach has been illustrated by 
the subsequent success of his program and its many contributions to the growth 
and policies of the field. 
Starzl, T. E., and Demetris, A. J. (Eds.): Uver Transplantation. Chicago, Mosby-
Year Book Inc .. 1990, pp. 1-194. 
A three-part modern day account of liver transplantation published in Cu.rrent 
Problems in Surgery was converted to this textboole. The vast literature of the 
topic was summarized through the end of 1989, including the adtlancts made 
possible with the UW preservation solution, lind the first trials with the new 
immunosuppressi"e agent FK 506. An extensive update is included about develop-
ments in liver transplantation pathology. 
StarzI, T. E., Porter, K. A., and Francavilla. A.: The Ed fistula in animals and 
humans. Curro Probl. Surg., 20(11):687, 1983. 
This monograph describes knowledge of the so-called hepatotrophic substances 
found in portal tlenous blood and describes the specific effects of tltnous blood from 
nonhepatic splanchnic organs in regulating liver structure and function. Hepato-
tropic physiology was dttleloped liS /I consequence of research in lIuxiliary liver 
transplantation. and the resulting background is essential to an understanding of 
the physiology lind tlllscularization requirements if auxiliary liver grafts are to be 
used. 
Williams, J. W. (Ed.): Hepatic Transplantation. Philadelphia, W. B. Saunders 
Company, 1990, pp. 1-245. 
In the late 19705, Williams established at the Unitlersity of Tennessee the second 
successful liver transplant program in the United States. He moved in 1984 10 his 
present location at the Rush Presbyterian-St. Luke's Medical Center in Chicago. 
This book refiects Williams' passion tor this kind of treatment, not only now when it 
is respectable. but at an earlier time when it was not. Williams' contributions to the 
field hlltle been many, and perhaps less well recognized than their uniformly high 
quality and common sense merit. 
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PANCREAS TRANSPLANTATION 
Hans W. Sollinger, M.D., Ph.D., and Mark Stegall, M.D. 
HISTORICAL ASPECTS 
According to Erich Lexer, the first surgical step in treating 
Type I diabetes mellitus by transplantation of the pancreas was 
in 1891, 30 years before the discovery of insulin. An English 
surgeon, Williams, transplanted extracts of sheep pancreas into 
the abdominal wall of a comatose diabetic patient and his early 
trial demonstrates that the concept of replacing non functioning 
islets by means of transplantation of vital endocrine tissue is a 
very old one. The first clinical pancreas transplant was per-
fonned by Kelly and Wlehei on December 17, 1966.8 The type 
of transplant was a segmental graft transplanted to the iliac 
fossa with the pancreatic duct ligated. In 1973, Gliedman and 
associates6 suggested for the first time the use of the urinary 
tract for exocrine pancreatic drainage. Merkel and colleagues9 
reported end-to-side anastomosis of the pancreatic duct to the 
ureter, with the belief that this would obviate the need for na-
tive nephrectomy when transplantation is perfonned in a non-
uremic patient. In the mid 1970s the Stockholm group, headed 
by Groth, embarked on a larger series of enterically drained 
grafts.7 A new method of handling exocrine secretions was sug-
gested by Dubernard and associates.s They thought exocrine 
secretions could be obliterated by injecting the pancreatic duct 
with a polymer. In 1982, Cook and Sollinger, from the Univer-
sity of Wisconsin, suggested channeling of the exocrine secre-
tions to the urinary bladder. In their initial clinical experience, 
the pancreatic duct of a segmental graft was sutured to the 
bladder mucosa. They later turned to whole pancreatic grafts, 
using the duodenal button technique, and, more recently, to the 
duodenal segment method as described by Nghiem and asso-
ciates.11 Other techniques of managing exocrine pancreatic se-
cretions are enterically drained pancreaticoduodenal grafts, 
paratopic grafting with exocrine drainage into the stomach·, 
and a variety of modifications of the bladder technique such as 
skeletonizing the pancreatic duct prior to implantation into the 
bladder, by the Goteborg group,14 or implanting the entire cut 
edge of the pancreas end-to-side into the bladder. 
INDICATIONS 
The indications for transplantation of the pancreas remain 
controversial. It can be perfonned in three settings: alone in the 
preuremic patient; after successful kidney grafting; and simul-
taneously with a kidney transplant. Clearly, pancreas trans-
plantation should be perfonned before the patient develops 
end-stage secondary complications such as advanced retinop-
athy leading to blindness, disabling neuropathy, end-stage ne-
phropathy, or extensive macrovascular and microvascular dis-
ease. In the authors' view, pancreas transplantation in the 
preuremic patient is justified only in a setting in which careful 
long-tenn monitoring of its potential effect on secondary com-
plications can be perfonned. These studies must include exten-
sive investigation and monitoring of the progression of retinop-
athy and nephropathy. Transplantation of the pancreas after 
successful transplantation of the kidney has the advantage that 
the patient is already on immunosuppressive therapy. Unfortu-
nately, the results of preuremia and sequential grafting are sig-
nificantly worse than the results in combined transplantation of 
kidney and pancreas. For this reason, the majority of pancreas 
transplants in the past years have been combined transplants. 
In this setting, only one surgical procedure is required, and the 
patient receives an immunosuppressive regimen similar to that 
of a patient undergoing a kidney transplant alone. Absolute 
contraindications for pancreas transplantation are similar to the 
contraindications for kidney transplantation. They include the 
presence of malignancy and active infection. Patients with ad-
vanced cardiovascular disease, major amputations, blindness, 
and inability to understand the investigational nature of the 
procedure are excluded in the authors' program. Of major im-
portance is the evaluation of the patient's cardiac status, be-
cause many diabetic patients, as a result of neuropathy, do not 
present with the classic symptoms of angina, even in the pres-
ence of advanced coronary artery disease. Therefore, preopera-
tive evaluation requires thallium stress testing in all patients 
over the age of 30. If the thallium stress test is suggestive of 
